Cetuximab single-agent activity in refractory metastatic colorectal cancer: Single-center experience

Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas

“…Cetuximab (C-225, Erbitux®, Merck) is a monoclonal antibody with a high affinity to EGF-R that has shown direct inhibition of tumor growth and angiogenesis in preclinical trials. Clinical trials on patients with colorectal cancer who failed all standard therapy have shown a disease control rate of 46% with a partial response of 12% and only minor side effects [14,15]. These results were confirmed in a randomized phase III study with an even higher response when inhibition of EGF-R was combined with Irinotecan [16].…”

Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?

“…In a study by Saltz et al, 57 patients with EGFR-positive colorectal cancer refractory to both Fluorouracil and Irinotecan, achieved an 8.8% partial response (PR) to Cetuximab monotherapy, and 36.8% had stable disease [40]. During the 40th ASCO Annual Meeting, three studies evaluated the role of Cetuximab in patients [42,43]. Of most interest is Cetuximab's ability to reverse cellular resistance to Irinotecan, Saltz et al showed a 17% RR [44] with weekly Cetuximab and Irinotecan in 121 patients with colorectal cancer who had been refractory to Fluorouracil and Irinotecan.…”

“…Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Beva: Bevacizumab; FOLFOX4: Fluorouracil/Leucovorin/Oxaliplatin; OS: overall survival; PS: performance status.who failed all standard therapy[41][42][43]. Lenz et al evaluated 350 patients refractory to both Irinotecan and Oxaliplatin.…”